Frederick Munschauer
Overview
Explore the profile of Frederick Munschauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zivadinov R, Cookfair D, Krupp L, Miller A, Lava N, Coyle P, et al.
BMC Neurol
. 2016 Jul;
16:102.
PMID: 27416843
Background: This retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up. Methods: Patients from the centralized New York...
2.
Sternberg Z, Chichelli T, Sternberg D, Sawyer R, Ching M, Janicke D, et al.
J Stroke Cerebrovasc Dis
. 2015 Nov;
25(2):327-34.
PMID: 26586373
Objective: We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with...
3.
Sternberg Z, Chichelli T, Sternberg D, Hojnacki D, Drake A, Liu S, et al.
Atherosclerosis
. 2013 Nov;
231(2):411-20.
PMID: 24267260
Aims: This cross-sectional study tested the hypothesis that treatment with the combination of Ezetimibe/Simvastatin (Vytorin) leads to broader changes in the expression levels of immunomodulatory genes as compared to Simvastatin...
4.
Sternberg Z, Ghanim H, Gillotti K, Tario Jr J, Munschauer F, Curl R, et al.
Atherosclerosis
. 2013 Jul;
229(2):338-47.
PMID: 23880185
Objectives: The relative contribution of the local vs. peripheral inflammation to the atherothrombotic processes is unknown. We compared the inflammatory status of the immune cells of the carotid plaque with...
5.
Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F
Immunol Invest
. 2010 Nov;
40(2):197-205.
PMID: 21080832
This pilot study used immunohistochemical techniques to investigate the advanced glycation end-product (AGE) Nepsilon-(carboxymethyl)lysine (CML) and its receptor (RAGE) in the brains of multiple sclerosis (MS) patients, comparing them with...
6.
Sternberg Z, Hennies C, Sternberg D, Wang P, Kinkel P, Hojnacki D, et al.
J Neuroinflammation
. 2010 Nov;
7:72.
PMID: 21034482
Background: This study compared the level of advanced glycation end products (AGEs), N-(Carboxymethyl)lysine (CML) and N-(Carboxyethyl)lysine (CEL), in patients with multiple sclerosis (MS) and healthy controls (HCs), correlating these markers...
7.
Sternberg Z, Hennies C, Sternberg D, Bistulfi G, Kazim L, Benedict R, et al.
Mult Scler
. 2010 Oct;
17(2):157-63.
PMID: 20965962
Background: The chronic inflammation associated with multiple sclerosis (MS) may lead to the upregulation of pentosidine. Objectives: This cross-sectional study compares plasma pentosidine levels among healthy controls (HCs) and patients...
8.
Morrow S, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict R
Clin Neuropsychol
. 2010 Sep;
24(7):1131-45.
PMID: 20830649
Cognitive dysfunction is common in multiple sclerosis (MS), yet the magnitude of change on objective neuropsychological (NP) tests that is clinically meaningful is unclear. We endeavored to determine NP markers...
9.
Sternberg Z, Chadha K, Lieberman A, Drake A, Hojnacki D, Weinstock-Guttman B, et al.
J Neuroinflammation
. 2009 Oct;
6:28.
PMID: 19825164
The study is aimed to determine the role of luteolin (3',4',5,7-tetrahydroxyflavone), alone and in combination with human interferon-beta (IFN-beta), in modulating the immune response(s) of peripheral blood mononuclear cells (PBMCs)...
10.
Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, Feichter J, et al.
J Neuroimmunol
. 2008 Oct;
205(1-2):113-25.
PMID: 18950872
Purpose: To characterize gene expression in multiple sclerosis (MS) patients after the first dose and chronic dosing of 30 microg, once weekly, intramuscular interferon-beta1a (IFN-beta) and to delineate the pharmacogenomic...